Fleischmann WR Jr - Search Results

1

Heterogeneous interleukin-15 inducibilities in murine B16 melanoma and RM-1 prostate carcinoma by interferon-alpha treatment.

Wu TG, Perdigão JR, Umhoefer TK, Cao J, Ansari DA, Albrecht TB, Knutson EP, Rose WA 2nd, Jorgensen AJ, Ryan LM, Abdalla LE, Fleischmann WR Jr. Wu TG, et al. Among authors: fleischmann wr jr. J Interferon Cytokine Res. 2009 Nov;29(11):719-28. doi: 10.1089/jir.2008.0073. J Interferon Cytokine Res. 2009. PMID: 19642895 Free PMC article.

2

IFN-alpha-induced murine B16 melanoma cancer vaccine cells: induction and accumulation of cell-associated IL-15.

Wu TG, Rose WA 2nd, Albrecht TB, Knutson EP, König R, Perdigão JR, Nguyen AP, Fleischmann WR Jr. Wu TG, et al. Among authors: fleischmann wr jr. J Interferon Cytokine Res. 2007 Jan;27(1):13-22. doi: 10.1089/jir.2007.0039. J Interferon Cytokine Res. 2007. PMID: 17266439

3

Development of an interferon-based cancer vaccine protocol: application to several types of murine cancers.

Fleischmann WR Jr, Wu TG. Fleischmann WR Jr, et al. Methods Mol Med. 2005;116:151-66. doi: 10.1385/1-59259-939-7:151. Methods Mol Med. 2005. PMID: 16000860

4

Murine B16 melanoma vaccination-induced tumor immunity: identification of specific immune cells and functions involved.

Wu TY, Fleischmann WR Jr. Wu TY, et al. Among authors: fleischmann wr jr. J Interferon Cytokine Res. 2001 Dec;21(12):1117-27. doi: 10.1089/107999001317205259. J Interferon Cytokine Res. 2001. PMID: 11798470

5

Systemic effects of orally administered interferons and interleukin-2.

Fleischmann WR Jr, Koren S. Fleischmann WR Jr, et al. J Interferon Cytokine Res. 1999 Aug;19(8):829-39. doi: 10.1089/107999099313334. J Interferon Cytokine Res. 1999. PMID: 10476926

6

Efficacy of B16 melanoma cells exposed in vitro to long-term IFN-alpha treatment (B16alpha cells) as a tumor vaccine in mice.

Wu TY, Fleischmann WR Jr. Wu TY, et al. Among authors: fleischmann wr jr. J Interferon Cytokine Res. 1998 Oct;18(10):829-39. doi: 10.1089/jir.1998.18.829. J Interferon Cytokine Res. 1998. PMID: 9809618

7

Lack of mda-6/WAF1/CIP1-mediated inhibition of cyclin-dependent kinases in interferon-alpha resistant murine B16 melanoma cells.

Arany I, Fleischmann CM, Tyring SK, Fleischmann WR Jr. Arany I, et al. Among authors: fleischmann wr jr. Cancer Lett. 1997 Nov 11;119(2):237-40. doi: 10.1016/s0304-3835(97)00288-7. Cancer Lett. 1997. PMID: 9570377

8

Orally administered IFN-alpha acts alone and in synergistic combination with intraperitoneally administered IFN-gamma to exert an antitumor effect against B16 melanoma in mice.

Fleischmann WR Jr, Masoor J, Wu TY, Fleischmann CM. Fleischmann WR Jr, et al. J Interferon Cytokine Res. 1998 Jan;18(1):17-20. doi: 10.1089/jir.1998.18.17. J Interferon Cytokine Res. 1998. PMID: 9475662

9

B16 melanoma cells exposed in vitro to long-term IFN-alpha treatment (B16 alpha cells) as activators of tumor immunity in mice.

Fleischmann CM, Wu TY, Fleischmann WR Jr. Fleischmann CM, et al. Among authors: fleischmann wr jr. J Interferon Cytokine Res. 1997 Jan;17(1):37-43. doi: 10.1089/jir.1997.17.37. J Interferon Cytokine Res. 1997. PMID: 9041470

10

Enhanced in vivo sensitivity of in vitro interferon-treated B16 melanoma cells to CD8 cells and activated macrophages.

Fleischmann CM, Stanton GJ, Fleischmann WR Jr. Fleischmann CM, et al. Among authors: fleischmann wr jr. J Interferon Cytokine Res. 1996 Oct;16(10):805-12. doi: 10.1089/jir.1996.16.805. J Interferon Cytokine Res. 1996. PMID: 8910765

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

78 results

Search Page